Juan Fernandez, MD
Nephrology · Miami, FLNPI 1568481620
Payments from drug & device makers
Across 549 payments — averaging $4563.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim Pharma GmbH & Co.kg$544K
- Boehringer Ingelheim$528K
- CSL Behring$520K
- Boehringer Ingelheim International GmbH$489K
- Akebia Therapeutics Inc$236K
- Vertex$88K
- plus $100K from 20 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim Pharma GmbH & Co.kg | 24 | $543,611 |
| Boehringer Ingelheim | 29 | $527,835 |
| CSL Behring | 106 | $520,058 |
| Boehringer Ingelheim International GmbH | 50 | $489,388 |
| Akebia Therapeutics Inc | 201 | $236,191 |
| Vertex | 3 | $88,336 |
| Travere Therapeutics, Inc. | 30 | $44,172 |
| Astrazeneca UK Limited | 1 | $23,511 |
| AstraZeneca | 21 | $22,001 |
| Amgen(2 entities) | 18 | $7,095 |
| Baxter Healthcare | 10 | $1,343 |
| GSK | 5 | $994 |
| Otsuka America Pharmaceutical, Inc. | 10 | $206 |
| Bayer | 7 | $137 |
| OPKO Pharmaceuticals, LLC | 7 | $125 |
| Harrow Eye, LLC | 4 | $112 |
| Lilly USA, LLC | 2 | $92 |
| Fresenius USA Marketing, Inc. | 5 | $83 |
| Vifor Pharma, Inc. | 4 | $79 |
| Calliditas Therapeutics US Inc. | 3 | $69 |
| Johnson & Johnson | 3 | $46 |
| Ardelyx, Inc. | 2 | $45 |
| Organogenesis Inc. | 1 | $30 |
| Kyowa Kirin, Inc. | 1 | $28 |
| Sanofi | 1 | $20 |
| Abbott | 1 | $14 |
How this compares
$2,505,620 in reported general payments places this provider in the 95th percentile of 756 nephrology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other nephrology in Miami
- Oscar GalvezMiami$14.2M
- Alessia FornoniMiami$2.1M
- Hassan AliMiami$1.4M
- Shadi TaraziMiami$739K
- Fernando TrespalaciosMiami$626K
- Manuel Garcia-EstradaMiami$476K
- Anne Marie MilesMiami$419K
- Gabriel ContrerasMiami$266K
- Jose Cardona-GuzmanMiami$245K
- Thomas MarburyOrlando$41.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.